by Phase 3 Trails of Sputnik V Vaccine Offer Hope for New COVID-19 Vaccine
Russia has been making strong claims by deeming Sputnik V as the first registered coronavirus (COVID-19) vaccine. However, the Union Health Ministry of India has denied Moscow’s claims about collaboration. As such, Russia is in talks to conduct phase 3 trials in different countries including India. The Gamaleya Research Institute and the Russia Defence Ministry are gaining recognition in the global respiratory virus vaccines market since President Putin announced the approval for Sputnik V coronavirus vaccine.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111844
However, the Sputnik V vaccine is under scrutiny since phase 1 clinical trials of the Russian vaccine have not been published in the scientific literature. However, phase 2 trials of Russian vaccine involved several civilians and military volunteers. Thus, researchers and scientists in the Russia respiratory virus vaccines market are focusing on the final stage of testing for Sputnik V vaccine, which will involve the participation of a large number of volunteers.
Strategic Collaborations Instrumental in Coronavirus Vaccine Experiments
Apart from Russia, the Serum Institute of India is being highly publicized for developing billions of COVID-19 vaccine doses. Chief executive officer Adar Poonawalla is gaining popularity around the world as the vaccine vanguard, since its facilities have the capacity to produce billions of doses per year. Thus, companies in the respiratory virus vaccines market are taking cues from the largest producers of vaccine in the world to brew the raw materials necessary to experiment with coronavirus vaccines. As such, analysts at opine that the COVID-19 vaccine will be ready for deployment worldwide at the earliest by 2022.
Companies in the respiratory virus vaccines market are joining forces with leading biotechnology firms to progress in the pre-clinical test phase. Since the Coronavirus strain is similar to the previous SARS virus, it is potentially easier for scientists to advance in the pre-clinical test phases.
Research Funding Helps in Development of Long-lasting Influenza Vaccines
The National Institute of Allergy and Infectious Diseases (NIAID) has announced to provide a funding of ~US$ 51 Mn for the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, in an effort to develop long-lasting influenza vaccines. Thus, research centers in the respiratory virus vaccines market are increasing efforts to set up collaborative research teams that develop more durable and broadly protective influenza vaccines. Constructive efforts by scientists and research centers are bolstering the respiratory virus vaccines market, which is anticipated to advance at a steady CAGR of ~8% during the assessment period.
There is a growing need to effectively fight off influenza on the global level. Hence, pharmaceutical companies are increasing their R&D capabilities to innovate in improved formulations for respiratory virus vaccines.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Virus Vaccines Market
Immunization Programs Significantly Reduce Mortality Rates for Measles
The World Health Organization (WHO) claims that immunization has become an important tool for innovation in measles vaccines. With the help of immunization, several million infants are being vaccinated against measles, thus lowering mortality rates worldwide. Companies in the respiratory virus vaccines market are developing promising vaccines that protect the health of individuals from tuberculosis and influenza. They are intensifying their R&D capabilities to develop neutralizing antibodies and therapeutic respiratory virus vaccines that can generate value-grab opportunities for manufacturers.
There is a growing demand for needle-free vaccine administration to suit the needs of adolescents, pregnant women, and other age groups. Moreover, there is a need for robust vaccine storage and supply chains that hold promising potentials to transform immunization programs in the upcoming decade. Thus, timely access to reliable data is found to provide exciting opportunities for companies in the respiratory virus vaccines market.
Large Investments Play Key Role in Validated Efficacy of Mumps Vaccines
A research done by Emory Vaccine Center and the Centers for Disease Control and Prevention indicates that immunity against mumps virus appears to be insufficient among a fraction of college-aged individuals who were previously vaccinated in their childhood. Thus, companies in the respiratory virus vaccines market are increasing efforts to better understand the immune response to mumps and mumps vaccines. In the past decade, it has been observed that several mumps outbreaks have occurred among sports teams, college students, and close-knit communities in the U.S. Hence, pharmaceutical companies are focusing on developing effective mumps vaccines to lower the rate of mumps outbreaks.
Lack of strong immune response pertaining to mumps vaccine has emerged as a challenge for companies in the respiratory virus vaccines market. Manufacturers are directing large investment in clinical trials to demonstrate the safety and efficacy of mumps vaccines.
New TB Vaccines Hold Promising Potentials in Preventing Mtb in Individuals
Mycobacterium tuberculosis (Mtb) is responsible for high mortality rates, which is the highest among any single infectious pathogen worldwide. Hence, there is a demand for tuberculosis vaccines, since Bacille Calmette Guerin (BCG) is the only licensed vaccine, which is approaching its centenary. Moreover, the BCG vaccine if found to offer little to no protection against adult-type pulmonary tuberculosis. This has created a scope for companies in the respiratory virus vaccines market who can innovate in new TB vaccines.
Pharmaceutical companies are following the Preferred Product Characteristics (PPC) developed by the WHO to identify target populations who can be promising candidates for steering innovation in TB vaccines. These involve the participation of adults, adolescents, and infants. Companies are focusing on developing new TB vaccines for use in mass campaigns that are efficacious in preventing TB among adults and adolescents.
Analysts’ Viewpoint
France’s Pasteur Institute is increasing its R&D activities to use modified measles vaccine to trick the body into producing antibodies that are capable of fighting COVID-19 pathogens. Since seasonal influenza leads to hospitalization of tens of thousands of individuals in the U.S., companies in the respiratory virus vaccines market are tapping into growth opportunities in this domain. However, it is found that the circulating strain has drifted away from the strain that is in the mumps vaccine, which has led to mumps outbreaks among college institutes in the U.S. Hence, companies should invest in clinical trials to generate the desired immune response among individuals.
Respiratory Virus Vaccines Market: Overview
The global respiratory virus vaccines market for the historical year (2018), base year (2019), and the forecast period (2020-2030), increase in incidence of respiratory infections is projected to drive the global respiratory virus vaccines market in the near future
According to the report, the global respiratory virus vaccines market was valued at US$ 6.4 Bn in 2019. It is anticipated to expand at a CAGR of ~8% from 2020 to 2030
In terms of type, the global respiratory virus vaccines market has been classified into inactivated/killed vaccines, live-attenuated vaccines, and recombinant vaccines. Based on route of administration, the global respiratory virus vaccines market has been categorized into intramuscular, intranasal, and subcutaneous. In terms of indication, the global respiratory virus vaccines market has been classified into influenza, measles, mumps & rubella, coronavirus disease (COVID-19), and others. In terms of age group, the global respiratory virus vaccines market has been divided into pediatric and adults. In terms of end user, the global respiratory virus vaccines market has been classified into physician offices, hospitals, clinics, pharmacies/stores, and others.
Increase in Burden of Respiratory Illnesses to Drive Respiratory Virus Vaccines Market
Rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections, and large number of pharmaceutical companies participating in the race to develop vaccine for the novel coronavirus are major factors projected to boost the respiratory virus vaccines market during the forecast period
As per the World Health Organization, 290,000 to 650,000 people die globally, every year, due to flu-related illnesses
Government Initiatives to Expand Vaccination Coverage to Propel Respiratory Virus Vaccines Market
In April 2017, the Government of Canada announced its decision to invest C$ 1.7 Mn in the Immunization Partnership Fund in order to fund three new projects aimed at expanding the vaccination coverage in Canada
In February 2017, the Government of India launched the ‘Pan-India campaign for Measles-Rubella Vaccination’ to help protect children from major childhood diseases viz. rubella and measles. This nationwide vaccination campaign aims to administer measles-rubella vaccine (MR-VAC) to children aged between nine months and 15 years of age.
Respiratory Virus Vaccines Market: Competition Landscape
This report profiles major players operating in the global respiratory virus vaccines market based on attributes such as company overview, financial overview, product portfolio, major brands, business strategies, and recent developments
The global respiratory virus vaccines market is marked by the presence of a few large players operating in the international market and some small players in regional markets. The top players hold a major share of the global respiratory virus vaccines market.
Developing a vaccine for the novel coronavirus has become a need of an hour. Amid the coronavirus crisis, several pharmaceutical companies are developing vaccine for COVID-19, with promising drug candidate in phase I and phase II in clinical trials.
Prominent players operating in the global respiratory virus vaccines market include –
- CSL Limited
- Sanofi
- AstraZeneca
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Sinovac Biotech Ltd.
Key Questions Answered in Respiratory Virus Vaccines Market Report
- What are the major drivers, restraints, and opportunities in the global respiratory virus vaccines market?
- What is the revenue share projection of key segments of the global respiratory virus vaccines market during the forecast period?
- Which segment is likely to lead the global respiratory virus vaccines market in terms of revenue between 2020 and 2030?
- How mergers & acquisitions among players are widening the scope of the global respiratory virus vaccines market?
- What is the market position of different companies operating in the global respiratory virus vaccines market?
Respiratory Virus Vaccines Market – Segmentation
Type
- Inactivated/Killed Vaccines
- Live-attenuated Vaccines
- Recombinant Vaccines
Route of Administration
- Intramuscular
- Intranasal
- Subcutaneous
Indication
- Influenza
- Measles, Mumps & Rubella
- Coronavirus Disease (COVID-19)
- Others
Age Group
- Pediatric
- Adults
End User
- Physician’s Office
- Hospitals
- Clinics
- Pharmacies/Stores
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111844/2900
